Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.22.1
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Total revenue $ 45,693 $ 55,150
Royalties    
Disaggregation of Revenue [Line Items]    
Total revenue 13,695 7,112
Kyprolis    
Disaggregation of Revenue [Line Items]    
Total revenue 4,622 4,287
Evomela    
Disaggregation of Revenue [Line Items]    
Total revenue 2,701 2,333
Teriparatide injection    
Disaggregation of Revenue [Line Items]    
Total revenue 2,911 16
Rylaze    
Disaggregation of Revenue [Line Items]    
Total revenue 1,649 0
Other    
Disaggregation of Revenue [Line Items]    
Total revenue 1,812 476
Captisol    
Disaggregation of Revenue [Line Items]    
Total revenue 12,122 31,272
Captisol - Core    
Disaggregation of Revenue [Line Items]    
Total revenue 6,226 1,253
Captisol - COVID    
Disaggregation of Revenue [Line Items]    
Total revenue 5,896 30,019
Contract revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 19,876 16,766
Service Revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 5,146 5,462
License Fees    
Disaggregation of Revenue [Line Items]    
Total revenue 3,086 1,043
Milestone    
Disaggregation of Revenue [Line Items]    
Total revenue 9,089 8,417
Other    
Disaggregation of Revenue [Line Items]    
Total revenue $ 2,555 $ 1,844